Danatlas Pharmaceuticals announced that the first subject has been enrolled and dosed in the Phase II clinical study of DAT‑2645, the company’s independently developed Class 1 innovative drug, at the lead site Cancer Hospital, Chinese Academy of Medical Sciences (CAMS). The multicentre trial evaluates DAT‑2645 in patients with advanced/metastatic ovarian cancer harbouring BRCA1/2 loss‑of‑function mutations and/or homologous recombination deficiency (HRD) positivity – a population that currently lacks effective treatment options.
Trial Initiation Snapshot
| Item | Detail |
|---|---|
| Company | Danatlas Pharmaceuticals (private) |
| Product | DAT‑2645 – independently developed Class 1 innovative drug |
| Milestone | First subject enrolled and dosed (first patient in, FPI) |
| Lead Site | Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) |
| Trial Design | Multicentre, dose‑expansion, single‑arm Phase II |
| Target Population | Advanced/metastatic ovarian cancer with BRCA1/2 loss‑of‑function mutation and/or HRD‑positive status |
| Objectives | Anti‑tumour activity and safety profile |
| Date | 24 August 2026 |
Drug Profile & Clinical Rationale
- Molecule: DAT‑2645, a proprietary Class 1 new molecular entity developed in‑house by Danatlas.
- Biomarker‑Defined Population: Enrolment requires confirmed BRCA1/2 loss‑of‑function mutations (pathogenic or likely pathogenic; germline or somatic) or HRD positivity by validated assays – aligning the trial with precision‑oncology stratification.
- Unmet Need: The study aims to deliver a new targeted treatment option for ovarian cancer patients whose disease has progressed after, or who cannot tolerate, standard therapy.
- Post‑PARP Setting: Patients may enrol regardless of prior PARP inhibitor exposure (e.g., olaparib, fluzoparib, talazoparib), positioning DAT‑2645 as a potential option after PARP inhibitor failure.
- Mechanism: Target and mechanism details are not disclosed in the announcement; company pipeline context indicates a transcription‑factor/DNA‑damage‑response focus – full profile to be detailed in future disclosures.
Key Eligibility Criteria
| # | Criterion |
|---|---|
| 1 | Understands and voluntarily participates; signed informed consent form (ICF) |
| 2 | Female, aged ≥ 18 years |
| 3 | Histologically or cytologically confirmed epithelial ovarian cancer |
| 4 | Confirmed BRCA1/2 loss‑of‑function mutation (pathogenic/likely pathogenic; germline or somatic) or HRD‑positive by a validated assay |
| 5 | Failed or intolerant to prior standard treatment |
| 6 | Eligible with or without prior PARP inhibitor therapy (olaparib, fluzoparib, talazoparib, etc.) |
Market Impact & Outlook
- Precision Oncology Positioning: A biomarker‑selected single‑arm design in a refractory population can support an accelerated development pathway should activity signals emerge.
- Competitive Landscape: With enrolment open to PARP inhibitor–pretreated patients, DAT‑2645 addresses a recognised gap in the post‑PARP ovarian cancer setting, where treatment options remain limited.
- Pipeline Momentum: The FPI milestone adds to Danatlas’s growing clinical portfolio, following the recent IND approval of DAT‑6618 (September 2026), reinforcing the company’s focus on novel targets in solid tumours.
- Execution Signal: Successful first‑patient dosing at a leading national cancer centre demonstrates the company’s clinical operations capability in multicentre oncology trials.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding DAT‑2645’s clinical development, trial enrolment, and therapeutic potential. Actual results may differ due to risks including safety findings, efficacy outcomes, regulatory requirements and competitive dynamics in the ovarian cancer treatment market.-Fineline Info & Tech
